Onconetix Inc (ONCO) Stock Price, Quote & News

Company Profile

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, I...

Industry: Biotechnology

Sector: Healthcare

Phone: 513 620 4101

Website: www.onconetix.com

Address:

201 East Fifth Street, Suite 1900, Cincinnati, United States

Acdwqw Jul. 18 at 2:29 AM

$ONCO anyone experienced with this type of deal? I don’t see pure dilution, there are massive assets adding to the combined company. Even at today market cap~$1.86M, the new company is valued at $18.6M, and it’s a late staged company soon to be commercialized.

0 · Reply

parkerbeck Jul. 17 at 10:57 PM

$ONCO it’ll fly when we least expect it too.

1 · Reply

mymy2009 Jul. 17 at 8:14 PM

$ONCO 🟢 Ocuvex got a great pipeline All three products are either already commercial (Omlonti) or on the cusp of launch (PDP‑716, SDN‑037) in 2025. one commercial product in glaucoma and two late-stage therapies poised for market entry in 2025 https://ocuvextherapeutics.com/pipeline/

0 · Reply

mymy2009 Jul. 17 at 8:05 PM

$ONCO 🟢 Altos Venture AG announced an increase in its ownership in Onconetics by acquiring an additional 241,514 shares of common stock on July 14, 2025, pursuant to a "full consideration" clause in a subscription agreement dated December 15, 2023. This adjustment was made following two reverse stock splits on September 24, 2024, and June 13, 2025. This transaction was submitted on July 16, 2025, by Tobias Fischli, authorised signatory for Altos Venture AG. https://www.sec.gov/Archives/edgar/data/1782107/000141588925019831/xslF345X05/form4-07162025_080748.xml

0 · Reply

Najoua233902 Jul. 17 at 4:38 PM

$ONCO this should be more than enough for it to Squeez 41% SI if accurate is insane

0 · Reply

PremarketAddict Jul. 17 at 2:50 PM

news update: $ONCO Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement $SCNX Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements $QLGN Qualigen Granted New Patents Covering 25 Countries

0 · Reply

parkerbeck Jul. 17 at 2:32 PM

$ONCO im out of cheddar to add, just waiting for our lift off.

0 · Reply

MGeronimo Jul. 17 at 2:29 PM

$ONCO adding on the dip

0 · Reply

TheWayISeeIt Jul. 17 at 2:10 PM

$ONCO $VLCN

0 · Reply

moneyonmymintd Jul. 17 at 1:52 PM

$ONCO come to $ONCO from $VLCN

0 · Reply

Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement

Jun 16, 2025, 8:22 AM EDT - 4 weeks ago

Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel

Jun 11, 2025, 11:30 AM EDT - 5 weeks ago

Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders

May 22, 2025, 4:50 PM EDT - 2 months ago

Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq

May 22, 2025, 10:00 AM EDT - 2 months ago

Onco-Innovations Uplists to Cboe Canada

Mar 24, 2025, 8:45 AM EDT - 4 months ago

Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort

Mar 19, 2025, 8:00 AM EDT - 4 months ago

Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress

Dec 12, 2024, 5:00 PM EST - 7 months ago

Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing

Oct 8, 2024, 5:00 AM EDT - 10 months ago

Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

ENTO OCS VRNA

Oct 3, 2024, 4:45 PM EDT - 10 months ago

Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Oct 3, 2024, 9:05 AM EDT - 10 months ago

Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit

Sep 27, 2024, 2:41 PM EDT - 10 months ago

Crude Oil Rises; Onconetix Shares Spike Higher

Sep 20, 2024, 11:45 AM EDT - 10 months ago

Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of Stockholders

Jul 15, 2024, 6:00 AM EDT - 1 year ago

Onconetix Announces Closing of Warrant Exercise for $1.11 Million Gross Proceeds

Jul 11, 2024, 8:17 AM EDT - 1 year ago

Onconetix Announces Exercise of Warrants for $1.11 Million Gross Proceeds

Feb 13, 2024, 6:00 AM EST - 1 year ago

Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors

Dec 19, 2023, 7:00 AM EST - 1 year ago

Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

Dec 18, 2023, 7:00 AM EST - 1 year ago

Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

Nov 2, 2023, 7:00 AM EDT - 1 year ago

Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company

Nov 1, 2023, 7:00 AM EDT - 1 year ago

Blue Water Biotech Announces It Has Regained Compliance with Nasdaq Listing Rule 5250(c)(1)

Oct 30, 2023, 7:00 AM EDT - 1 year ago

Blue Water Biotech Issues Letter to Shareholders

Oct 10, 2023, 9:00 AM EDT - 1 year ago

Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO

Aug 28, 2023, 4:30 PM EDT - 2 years ago

Blue Water Biotech, Inc. Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Aug 3, 2023, 1:02 PM EDT - 2 years ago

Blue Water Biotech Announces Closing of Warrant Exercise and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Aug 1, 2023, 8:00 AM EDT - 2 years ago

Blue Water Biotech Announces Exercise of Warrants and Issuance of New Warrants in A Private Placement For $2.7 Million Gross Proceeds

Jul 31, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech and Knipper Health Join Forces to Distribute Samples for ENTADFI® and ZONTIVITY® to Physicians

Jul 25, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Teams with UpScriptHealth to Launch Telemedicine Platform for Benign Prostatic Hyperplasia Asset, ENTADFI®

Jul 17, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Issues CEO Shareholder Letter Providing Update on Commercial Launch Activities

Jul 11, 2023, 9:00 AM EDT - 2 years ago

Blue Water Biotech Teams with Advantage Point Solutions to Provide Healthcare Payer Coverage Support

Jul 6, 2023, 5:05 PM EDT - 2 years ago

Blue Water Biotech Secures License from Ohio State Board of Pharmacy to Operate as Pharmaceutical Wholesaler for its FDA Approved Products

Jul 6, 2023, 7:30 AM EDT - 2 years ago

Blue Water Biotech Teams with BFW Advertising to Market and Advertise Commercial Product Portfolio

Jun 28, 2023, 7:55 AM EDT - 2 years ago

Blue Water Biotech Announces Preclinical Data Supporting Immunogenicity of Novel Monkeypox Vaccine Utilizing Norovirus Virus-Like Particle Platform

Jun 21, 2023, 7:30 AM EDT - 2 years ago

Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio

Jun 14, 2023, 7:30 AM EDT - 2 years ago

Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas

May 12, 2023, 6:32 PM EDT - 2 years ago

Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 10, 2023, 12:15 PM EDT - 2 years ago

Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY

Apr 26, 2023, 3:44 PM EDT - 2 years ago

Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer

Apr 25, 2023, 8:00 AM EDT - 2 years ago

Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®

Apr 24, 2023, 8:00 AM EDT - 2 years ago

Blue Water Vaccines Announces Corporate Name Change to Blue Water Biotech in Connection with Transition into Commercial-Stage Biotechnology Company

Apr 20, 2023, 7:30 AM EDT - 2 years ago

Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset

Apr 12, 2023, 8:30 AM EDT - 2 years ago

Blue Water Vaccines Announces Signing of Sponsored Research Agreement with The University of Texas Health Science Center at San Antonio to Initiate Non-Human Primate Study for Live Attenuated, Orally Delivered Chlamydia Vaccine

Mar 9, 2023, 8:30 AM EST - 2 years ago

Blue Water Vaccines Reports Year 2022 Financial Results and Recent Business Highlights

Feb 6, 2023, 10:15 AM EST - 2 years ago

Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development

Feb 1, 2023, 9:15 AM EST - 2 years ago

Blue Water Vaccines Announces Partnership with AbVacc for Joint Development of Novel Monkeypox and Marburg Vaccine Candidates

Jan 17, 2023, 8:30 AM EST - 2 years ago

Blue Water Vaccines Announces Appointment of Seasoned Public Market and Private Equity Investment Leader Timothy Ramdeen to Board of Directors

Jan 9, 2023, 8:30 AM EST - 2 years ago

Blue Water Vaccines to Present at Biotech Showcase 2023 During the 41st Annual J.P. Morgan Healthcare Conference Week in San Francisco

Dec 12, 2022, 8:30 AM EST - 2 years ago

Blue Water Vaccines Announces Institutional Research Coverage by Two Notable Healthcare-Focused Wall Street Banks, Receives “Buy” Rating From Both

Dec 6, 2022, 8:30 AM EST - 2 years ago

Blue Water Vaccines Organizes Key Opinion Leader Event to Discuss Unmet Need for Acute Otitis Media and Pneumonia Vaccine and Its Streptococcus pneumoniae Vaccine Candidate

Dec 1, 2022, 8:30 AM EST - 2 years ago

Blue Water Vaccines to Present Update on Novel, Live Attenuated, Intranasally Delivered Streptococcus pneumoniae Vaccine to Prevent Acute Otitis Media, Pneumococcal Pneumonia, and Invasive Pneumococcal Disease at the World Vaccine & Immunotherapy Congress

Acdwqw Jul. 18 at 2:29 AM

0 · Reply

parkerbeck Jul. 17 at 10:57 PM

$ONCO it’ll fly when we least expect it too.

1 · Reply

mymy2009 Jul. 17 at 8:14 PM

0 · Reply

mymy2009 Jul. 17 at 8:05 PM

0 · Reply

Najoua233902 Jul. 17 at 4:38 PM

$ONCO this should be more than enough for it to Squeez 41% SI if accurate is insane

0 · Reply

PremarketAddict Jul. 17 at 2:50 PM

0 · Reply

parkerbeck Jul. 17 at 2:32 PM

$ONCO im out of cheddar to add, just waiting for our lift off.

0 · Reply

MGeronimo Jul. 17 at 2:29 PM

$ONCO adding on the dip

0 · Reply

TheWayISeeIt Jul. 17 at 2:10 PM

$ONCO $VLCN

0 · Reply

moneyonmymintd Jul. 17 at 1:52 PM

$ONCO come to $ONCO from $VLCN

0 · Reply

Najoua233902 Jul. 17 at 1:47 PM

$ONCO volatile 🔥 has zero shares left to short high short interest $VLCN low float

1 · Reply

Najoua233902 Jul. 17 at 1:40 PM

$ONCO oh boy if we get crypto reserve news that would take it to $50+

1 · Reply

moneyonmymintd Jul. 17 at 12:44 PM

$ONCO let's go 10$

0 · Reply

TheWayISeeIt Jul. 17 at 11:22 AM

$ONCO next $VLCN

1 · Reply

parkerbeck Jul. 17 at 11:05 AM

$ONCO the compliance pr would be nice

1 · Reply

JimBull Jul. 17 at 8:44 AM

Nano float stocks are hot! $VLCN no news , float 540k $XXII with news, float 500k other nano float stocks o watch: $ONCO merger news with 500K float $LGHL $APDN

0 · Reply

harry925 Jul. 17 at 3:11 AM

$ONCO

0 · Reply

LegendaryCharts Jul. 16 at 10:37 PM

$ONCO Merger news , swinging it

0 · Reply

theshortsqueezer2022 Jul. 16 at 10:29 PM

$BLBX 💰 $ONCO $BCDA

0 · Reply

theshortsqueezer2022 Jul. 16 at 10:17 PM

$ONCO I hope those mofos don’t dump their shares again like they did today in PM

0 · Reply

CallMeVon Jul. 16 at 10:17 PM

Swinging $RSLS into merger vote next week, hoping for a $XAGE/ $ONCO type gap on a halt🗞️ Also swinging $UPC this one is due for a run, small float could go like $WHLR did🤔

1 · Reply

StocHunter Jul. 16 at 9:56 PM

$ONCO

0 · Reply

Market Cap	1.87M
Revenue (ttm)	2.52M
Net Income (ttm)	-58.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,328.97%
Debt to Equity Ratio	0.00

Volume	393,500
Avg Vol	408,183
Day's Range	N/A - N/A
Shares Out	532,000.00
Stochastic %K	18%
Beta	3.38
Analysts	Strong Buy
Price Target	N/A